2025
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDY. Urologic Oncology Seminars And Original Investigations 2025, 43: 81. DOI: 10.1016/j.urolonc.2024.12.204.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerCarcinoma in situImpact of tumor stageBCG-unresponsiveRadical cystectomyUpfront RCCancer-specific mortalityOncological outcomesTumor stageT1 patientsAll-Cause MortalityTA patientsPathological outcomesPapillary diseaseHigh risk of recurrenceBCG-unresponsive diseaseClinical stage tumorsUpfront radical cystectomyClinical tumor stageNode-positive diseaseCompare oncologic outcomesInvasive bladder cancerT1 stage tumorsKaplan-Meier methodIMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT
Annapureddy D, Taylor J, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, O'Donnell M, Kamat A, Woldu S, Lotan Y. IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORT. Urologic Oncology Seminars And Original Investigations 2025, 43: 80-81. DOI: 10.1016/j.urolonc.2024.12.203.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle invasive bladder cancerBladder sparing therapyAll-Cause MortalityOncological outcomesRadical cystectomyCancer-specific mortalityNon-invasive diseaseBCG-unresponsiveBladder cancerPathological outcomesT1 diseaseT1 patientsCIS patientsMedian timeProgression to muscle-invasive bladder cancerBCG-unresponsive NMIBC patientsImpact of pathological stageImpact of tumor stageInternational cohortMuscle-invasive bladder cancerAssociated with significant morbiditySingle-institution seriesHeterogeneous group of patientsCompare oncologic outcomesINCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG
Narayan V, Boorjian S, Crispen P, Kamat A, Gomella L, Kates M, Karsh L, Master V, Richards K, Lerner S, Kim E, Inman B, Lane B, Schuckman A, Krupski T, Bardot S, Montgomery J, Busby J, Luchey A, Williams M, Agarwal P, Rehm D, Jakobsen J, Juul K, Dinney C. INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG. Urologic Oncology Seminars And Original Investigations 2025, 43: 86. DOI: 10.1016/j.urolonc.2024.12.217.Peer-Reviewed Original ResearchBCG-unresponsive NMIBCNon-muscle-invasive bladder cancerCystectomy-free survivalCarcinoma in situNadofaragene firadenovecPhase 3 studyCR statusBladder cancerKaplan-MeierPathological outcomesVector-based gene therapyMedian follow-up timeBladder-sparing optionsHigh-grade recurrenceYears of follow-upRate of upstagingKaplan-Meier (KMAssociated with morbidityData cutoffImmediate cystectomyTransurethral resectionPapillary tumorsOpen-labelDefinitive treatmentEfficacy analysis
2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson W, Barata P, Berg S, Signoretti S, Chang S, D’Andrea V, George D, Dzimitrowicz H, Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus G, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay R. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. The Oncologist 2023, 29: 870-877. PMID: 37368355, PMCID: PMC11448883, DOI: 10.1093/oncolo/oyad166.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaProgression-free survivalAmerican Joint Committee on CancerAdvanced renal cell carcinomaCytoreductive nephrectomyPathological outcomesCell carcinomaMedian progression-free survivalPathologic outcomes of patientsCorrelated to clinical variablesRetrospective study of patientsEra of immunotherapySurgical pathology outcomeMedian Follow-UpResponse Evaluation CriteriaKaplan-Meier methodOutcomes of patientsTime of surgeryFraction of patientsStudy of patientsStandard of careIO monotherapyPathological downstagingCell histology
2021
Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
Chan V, Tan W, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe J, Wang N, Leow J, Giannarini G, Vasdev N, Shariat S, Enikeev D, Ng C, Teoh J. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13: 3274. PMID: 34208888, PMCID: PMC8268689, DOI: 10.3390/cancers13133274.Peer-Reviewed Original ResearchNeoadjuvant hormonal therapyDelayed radical prostatectomyHigh-risk patientsRandomised controlled trialsRadical prostatectomyImmediate RPOncological outcomesCancer-specific survivalIntermediate-risk patientsMeta-analysisNewcastle-Ottawa ScaleDelayed RPIntermediate-riskNon-randomised controlled studiesRisk of biasOverall survivalHormone therapyWatchful waitingExpectant managementActive surveillanceCancer surgeryPathological outcomesNewcastle-OttawaLow riskObservational studyImprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules
Jimenez-Sainz J, Jensen RB. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules. Genes 2021, 12: 780. PMID: 34065235, PMCID: PMC8161351, DOI: 10.3390/genes12050780.Peer-Reviewed Original ResearchConceptsCancer riskFunctional assaysUncertain significanceSomatic BRCA2 mutationClinical decision ruleFuture cancer riskClinical decision processBRCA2 VUSBiochemical functional assaysClinical findingsTherapeutic optionsTreatment optionsPancreatic cancerBRCA2 mutationsClinical guidancePlatinum agentsPathological outcomesBenign naturePARP inhibitorsBRCA2 genesGermline mutationsPathological impactAccurate functional assaysBRCA2 variantsPatients
2020
New Insights Into Blood-Brain Barrier Maintenance: The Homeostatic Role of β-Amyloid Precursor Protein in Cerebral Vasculature
Ristori E, Donnini S, Ziche M. New Insights Into Blood-Brain Barrier Maintenance: The Homeostatic Role of β-Amyloid Precursor Protein in Cerebral Vasculature. Frontiers In Physiology 2020, 11: 1056. PMID: 32973564, PMCID: PMC7481479, DOI: 10.3389/fphys.2020.01056.Peer-Reviewed Original ResearchCerebral amyloid angiopathyΒ-amyloid precursor proteinBlood-brain barrierCentral nervous systemAlzheimer's diseaseBlood-brain barrier maintenanceΒ-amyloid accumulationPeripheral blood circulationPrecursor proteinEndothelial cell homeostasisCAA pathogenesisBBB dysfunctionBBB functionAmyloid angiopathyVascular dysfunctionAD onsetCerebrovascular homeostasisCerebral vasculatureVascular endotheliumPathological outcomesNervous systemHomeostatic roleBrain vasculatureNeurodegenerative disordersBarrier maintenance
2016
AI-22 Single cell protein and transcriptional profiling of CD4+ follicular B helper T (TFH) and central memory (TCM) cells in SLE: physiological and pathological phenotypes
Kwak M, Choi J, Kim S, Chen Z, Lee G, Craft J, Fan R. AI-22 Single cell protein and transcriptional profiling of CD4+ follicular B helper T (TFH) and central memory (TCM) cells in SLE: physiological and pathological phenotypes. Lupus Science & Medicine 2016, 3: a11. DOI: 10.1136/lupus-2016-000179.22.Peer-Reviewed Original ResearchCentral memory cellsTCM cellsTfh cellsSLE patientsHealthy donorsT cellsFollicular B helper T cellsSystemic lupus erythematosusCirculation of patientsHelper T cellsSLE T cellsLupus kidneysHumoral autoimmunityTranscriptional profilingIL-21Lupus erythematosusCytokine producersHelper TMurine lupusHumoral immunityLymphoid organsEnd organsLupus researchPathological outcomesTherapeutic target
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levels
2008
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
Brimo F, Vollmer R, Corcos J, Kotar K, Bégin L, Humphrey P, Bismar T. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53: 177-183. PMID: 18752501, DOI: 10.1111/j.1365-2559.2008.03087.x.Peer-Reviewed Original ResearchConceptsPathological stageTumor lengthPrognostic valueTumor extentFinal pathological stageHigher stage diseaseNeedle biopsy specimenCancer patient outcomesPrognostic significanceBiochemical recurrenceBiopsy specimenRadical prostatectomyPatient outcomesBiopsy reportingFailure statusCancer lengthPositive coresPathological outcomesLarger studyMorphometric measurementsDiscontinuous fociCancerCore tissuePatientsOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply